Laclimella

Dienogest and Estradiol valerate, the active ingredients in Laclimella, are a combined estrogen‑progestogen oral contraceptive presented as an oral tablet for oral use. It is indicated for prevention of pregnancy and may also help regulate menstrual cycles in women of reproductive age.

GNH USA supplies Laclimella as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Laclimella, a combined estrogen‑progestogen oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy.

- Contraception: Provides reliable prevention of pregnancy when taken as directed. - Menstrual cycle regulation: Helps establish more predictable menstrual bleeding patterns. - Hormonal acne improvement: May reduce acne associated with androgen excess.

Laclimella may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Headache - Breast tenderness - Weight gain - Mood changes - Irregular vaginal bleeding

Serious or Rare Side Effects: - Deep vein thrombosis - Pulmonary embolism - Stroke - Myocardial infarction - Severe allergic reaction (anaphylaxis) - Hepatic dysfunction

Before prescribing Laclimella, clinicians should consider several precautionary measures to ensure safe use.

- Assess cardiovascular risk: Evaluate history of thromboembolic disorders, hypertension, or smoking. - Review hepatic function: Avoid use in patients with active liver disease. - Consider smoking status: Contraindicated in women over 35 who smoke. - Monitor for hormone‑sensitive conditions: Use cautiously in breast or endometrial cancer history. - Counsel on medication adherence: Missed tablets increase failure risk. - Store at ambient temperature: Keep below 25 °C, in the original packaging, protected from moisture and light.

Laclimella can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): May reduce anticoagulant effect. - Enzyme‑inducing antiepileptics (phenytoin, carbamazepine): Decrease hormone levels, reducing efficacy. - Rifampin and St. John’s wort: Accelerate hormone metabolism, increasing risk of contraceptive failure.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors (SSRIs): May increase bleeding tendency. - Antifungal agents (ketoconazole, itraconazole): Can raise hormone concentrations. - Protease inhibitors (ritonavir): May alter hormonal levels, requiring closer monitoring.